PY314 + pembrolizumab

PY314 + pembrolizumab is a combination therapy under clinical investigation for the treatment of advanced solid tumors, including ovarian cancer. PY314 is a humanized monoclonal antibody that targets TREM2 (Triggering Receptor Expressed on Myeloid cells 2), leading to depletion of tumor-associated macrophages in the tumor microenvironment. Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by blocking PD-1 (programmed cell death protein 1) on lymphocytes, thereby enhancing anti-tumor immune responses. The combination aims to modulate both myeloid and lymphoid compartments of the immune system to improve anti-cancer efficacy. Early-phase clinical trials have shown acceptable safety profiles for this combination in heavily pretreated patients with advanced cancers[2][4][5].

Other names

none